1. Field of the Invention
This invention relates generally to medical devices, and, more particularly, to methods, apparatus, and systems for performing electrical signal therapy by a medical device.
2. Description of the Related Art
There have been many improvements over the last several decades in medical treatments for disorders of the nervous system, such as epilepsy and other motor disorders, and abnormal neural discharge disorders. One of the more recently available treatments involves the application of an electrical signal to reduce various symptoms or effects caused by such neural disorders. For example, electrical signals have been successfully applied at strategic locations in the human body to provide various benefits, including reducing occurrences of seizures and/or improving or ameliorating other conditions. A particular example of such a treatment regimen involves applying an electrical signal to the vagus nerve of the human body to reduce or eliminate epileptic seizures, as described in U.S. Pat. Nos. 4,702,254, 4,867,164, and 5,025,807 to Dr. Jacob Zabara, which are hereby incorporated in this specification in their entirety by reference.
More generally, the endogenous electrical activity (i.e., activity attributable to the natural functioning of the patient's own body) of a neural structure of a patient may be modulated in a variety of ways. In particular, the electrical activity may be modulated by exogenously applied (i.e., from a source other than the patient's own body) electrical, chemical, or mechanical signals applied to the neural structure. The modulation (hereinafter referred to generally as “neurostimulation” or “neuromodulation”) may involve the induction of afferent action potentials, efferent action potentials, or both, in the neural structure, and may also involve blocking or interrupting the transmission of endogenous electrical activity traveling along the nerve. Electrical signal therapy or electrical modulation of a neural structure (also known as “electrical signal therapy”) refers to the application of an exogenous therapeutic electrical signal (as opposed to a chemical or mechanical signal), to the neural structure. Electrical signal therapy may be provided by implanting an electrical device underneath the skin of a patient and delivering an electrical signal to a nerve such as a cranial nerve. The electrical signal therapy may involve performing a detection step, with the electrical signal being delivered in response to a detected body parameter. This type of stimulation is generally referred to as “active,” “feedback,” or “triggered” stimulation. Alternatively, the system may operate without a detection system once the patient has been diagnosed with epilepsy (or another medical condition), and may periodically apply a series of electrical pulses to the nerve (e.g., a cranial nerve such as a vagus nerve) intermittently throughout the day, or over another predetermined time interval. This type of stimulation is generally referred to as “passive,” “non-feedback,” or “prophylactic,” stimulation. The stimulation may be applied by an implantable medical device that is implanted within the patient's body.
A number of medical conditions that are amenable to electrical signal therapy via cranial nerve stimulation present symptoms in regions outside the brain. For example, disorders of the neurological system, the gastrointestinal system, the pancreas, or the kidneys feature impaired or improper function of those organs. Diabetes, particularly type I diabetes, often features impaired production of insulin by the islets of Langerhans in the pancreas. Electrical signal stimulation of either the brain alone or the organ alone may have some efficacy in treating such medical conditions, but may lack maximal efficacy.
Therefore, a need exists for apparatus and methods for performing electrical signal stimulation of both the brain and an organ outside the brain. A need also exists for apparatus and methods for performing electrical signal stimulation with increased efficacy.
In one aspect, the present invention relates to a method of treating a medical condition in a patient using an implantable medical device including coupling at least a first electrode and a second electrode to a cranial nerve of the patient, providing a programmable electrical signal generator coupled to the first electrode and the second electrode, generating a first electrical signal with the electrical signal generator, applying the first electrical signal to the electrodes, wherein the first electrode is a cathode and the second electrode is an anode, reversing the polarity of the first electrode and the second electrode, yielding a configuration wherein the first electrode is an anode and the second electrode is a cathode, generating a second electrical signal with the electrical signal generator, applying the second electrical signal to the electrodes, reversing the polarity of the first electrode and the second electrode, yielding a configuration wherein the first electrode is a cathode and the second electrode is an anode, generating a third electrical signal with the electrical signal generator, and applying the third electrical signal to the electrodes.
Each of the electrical signals can independently contain one or more pulses or one or more bursts. The number of pulses need not be equal between any two of the electrical signals.
In one aspect, in a method of neuromodulation effected by delivery to a cranial nerve of an electrical signal characterized by a number of electrical pulses, the present invention relates to an improvement including delivering a first electrical signal using a first electrode as a cathode and a second electrode as an anode; reversing the polarity of the first electrode and the second electrode, yielding a configuration wherein the first electrode is an anode and the second electrode is a cathode; delivering a second electrical signal using the first electrode and the second electrode; reversing the polarity of the first electrode and the second electrode, yielding a configuration wherein the first electrode is a cathode and the second electrode is an anode; and delivering a third electrical signal using the first electrode and the second electrode.
In one aspect, the present invention relates to a system for treating a medical condition in a patient, comprising at least two electrodes coupled to at least one cranial nerve of a patient, and an implantable device operatively coupled to the electrodes and comprising an electrical signal generator capable of applying an electrical signal to the cranial nerve using the electrodes to treat the medical condition and an electrode polarity reversal unit capable of reversibly reversing the configuration of the electrodes.
The invention may be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements, and in which:
While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that the description herein of specific embodiments is not intended to limit the invention to the particular forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
Illustrative embodiments of the invention are described herein. In the interest of clarity, not all features of an actual implementation are described in this specification. In the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the design-specific goals, which will vary from one implementation to another. It will be appreciated that such a development effort, while possibly complex and time-consuming, would nevertheless be a routine undertaking for persons of ordinary skill in the art having the benefit of this disclosure.
This document does not intend to distinguish between components that differ in name but not function. In the following discussion and in the claims, the terms “including” and “includes” are used in an open-ended fashion, and thus should be interpreted to mean “including, but not limited to.” Also, the term “couple” or “couples” is intended to mean either a direct or an indirect electrical connection. “Direct contact,” “direct attachment,” or providing a “direct coupling” indicates that a surface of a first element contacts the surface of a second element with no substantial attenuating medium there between. The presence of small quantities of substances, such as bodily fluids, that do not substantially attenuate electrical connections does not vitiate direct contact. The word “or” is used in the inclusive sense (i.e., “and/or”) unless a specific use to the contrary is explicitly stated.
The term “electrode” or “electrodes” described herein may refer to one or more stimulation electrodes (i.e., electrodes for delivering an electrical signal generated by an IMD to a tissue), sensing electrodes (i.e., electrodes for sensing a physiological indication of a patient's body), and/or electrodes that are capable of delivering a stimulation signal, as well as performing a sensing function.
Cranial nerve stimulation, such as vagus nerve stimulation (VNS), has been proposed to treat a number of medical conditions pertaining to or mediated by one or more structures of the nervous system of the body, including epilepsy and other movement disorders, depression, anxiety disorders and other neuropsychiatric disorders, dementia, head trauma, coma, migraine headache, obesity, eating disorders, sleep disorders, cardiac disorders (such as congestive heart failure and atrial fibrillation), hypertension, endocrine disorders (such as diabetes and hypoglycemia), and pain, among others. See, e.g., U.S. Pat. Nos. 4,867,164; 5,299,569; 5,269,303; 5,571,150; 5,215,086; 5,188,104; 5,263,480; 6,587,719; 6,609,025; 5,335,657; 6,622,041; 5,916,239; 5,707,400; 5,231,988; and 5,330,515. Despite the numerous disorders for which cranial nerve stimulation has been proposed or suggested as a treatment option, the fact that detailed neural pathways for many (if not all) cranial nerves remain relatively unknown, makes predictions of efficacy for any given disorder difficult or impossible. Moreover, even if such pathways were known, the precise stimulation parameters that would modulate particular pathways relevant to a particular disorder generally cannot be predicted.
In one embodiment, the present invention provides a method of treating a medical condition. The medical condition can be selected from the group consisting of epilepsy, neuropsychiatric disorders (including but not limited to depression), eating disorders/obesity, traumatic brain injury/coma, addiction disorders, dementia, sleep disorders, pain, migraine, endocrine/pancreatic disorders (including but not limited to diabetes), motility disorders, hypertension, congestive heart failure/cardiac capillary growth, hearing disorders, angina, syncope, vocal cord disorders, thyroid disorders, pulmonary disorders, gastrointestinal disorders, kidney disorders, and reproductive endocrine disorders (including infertility).
In a further embodiment, the medical condition is selected from the group consisting of gastrointestinal disorders, pancreatic disorders, kidney disorders, and diabetes.
Although not so limited, a system capable of implementing embodiments of the present invention is described below.
A stimulating nerve electrode assembly 125, preferably comprising at least an electrode pair, is conductively connected to the distal end of an insulated, electrically conductive lead assembly 122, which preferably comprises a pair of lead wires (one wire for each electrode of an electrode pair). Lead assembly 122 is attached at its proximal end to connectors on the header 116 (
In one embodiment, the open helical design of the electrode assembly 125 (described in detail in the above-cited Bullara patent), which is self-sizing and flexible, minimizes mechanical trauma to the nerve and allows body fluid interchange with the nerve. The electrode assembly 125 preferably conforms to the shape of the nerve, providing a low stimulation threshold by allowing a large stimulation contact area with the nerve. Structurally, the electrode assembly 125 comprises two electrode ribbons (not shown), of a conductive material such as platinum, iridium, platinum-iridium alloys, and/or oxides of the foregoing. The electrode ribbons are individually bonded to an inside surface of an elastomeric body portion of the two spiral electrodes 125-1 and 125-2 (
The elastomeric body portion of each loop is preferably composed of silicone rubber, and the third loop 128 (which typically has no electrode) acts as the anchoring tether for the electrode assembly 125.
The electrical pulse generator 110 may be programmed with an external computer 150 using programming software of a type known in the art for stimulating neural structures, or other suitable software based on the description herein, and a programming wand 155 to facilitate radio frequency (RF) communication between the computer 150 (
A variety of stimulation therapies may be provided in implantable medical systems 100 of the present invention. Different types of nerve fibers (e.g., A, B, and C-fibers being different fibers targeted for stimulation) respond differently to stimulation from electrical signals. More specifically, the different types of nerve fibers have different conduction velocities and stimulation thresholds and, therefore, differ in their responsiveness to stimulation. Certain pulses of an electrical stimulation signal, for example, may be below the stimulation threshold for a particular fiber and, therefore, may generate no action potential in the fiber. Thus, smaller or narrower pulses may be used to avoid stimulation of certain nerve fibers (such as C-fibers) and target other nerve fibers (such as A and/or B fibers, which generally have lower stimulation thresholds and higher conduction velocities than C-fibers). Additionally, techniques such as pre-polarization may be employed wherein particular nerve regions may be polarized before a more robust stimulation is delivered, which may better accommodate particular electrode materials. Furthermore, opposing polarity phases separated by a zero current phase may be used to excite particular axons or postpone nerve fatigue during long term stimulation.
As used herein, the terms “stimulating” and “stimulator” may generally refer to delivery of a signal, stimulus, or impulse to neural tissue for affecting neuronal activity of a neural tissue (e.g., a volume of neural tissue in the brain or a nerve). The effect of such stimulation on neuronal activity is termed “modulation”; however, for simplicity, the terms “stimulating” and “modulating”, and variants thereof, are sometimes used interchangeably herein. The effect of delivery of the stimulation signal to the neural tissue may be excitatory or inhibitory and may potentiate acute and/or long-term changes in neuronal activity. For example, the effect of “stimulating” or “modulating” a neural tissue may comprise one or more of the following effects: (a) changes in neural tissue to initiate an action potential (bi-directional or uni-directional); (b) inhibition of conduction of action potentials (endogenous or externally stimulated) or blocking the conduction of action potentials (hyperpolarizing or collision blocking), (c) affecting changes in neurotransmitter/neuromodulator release or uptake, and (d) changes in neuro-plasticity or neurogenesis of brain tissue. Applying an electrical signal to an autonomic nerve may comprise generating a response that includes an afferent action potential, an efferent action potential, an afferent hyperpolarization, an efferent hyperpolarization, an afferent sub-threshold depolarization, and/or an efferent sub-threshold depolarization.
In one embodiment, the stimulation method includes the steps of generating a first electrical signal with the electrical signal generator, applying the first electrical signal to the electrodes, wherein the first electrode is a cathode and the second electrode is an anode, reversing the polarity of the first electrode and the second electrode, yielding a configuration wherein the first electrode is an anode and the second electrode is a cathode, generating a second electrical signal with the electrical signal generator, applying the second electrical signal to the electrodes, reversing the polarity of the first electrode and the second electrode, yielding a configuration wherein the first electrode is a cathode and the second electrode is an anode, generating a third electrical signal with the electrical signal generator, and applying the third electrical signal to the electrodes.
In one embodiment, the first electrical signal, the second electrical signal, and the third electrical signal are substantially identical. In another embodiment, the first electrical signal may vary from the second electrical signal, the third electrical signal, or both in terms of one or more of pulse width, number of pulses, amplitude, frequency, stimulation on-time, and stimulation off-time, among other parameters.
The first electrical signal, the second electrical signal, and the third electrical signal are described herein in terms of exemplary illustrations. The person of ordinary skill in the art having benefit of the present disclosure would appreciate that more than three electrical signals, up to an nth electrical signal, can be used and are within the scope of the present invention.
“Cathode” and “anode” have their standard meanings, as the electrode at which current leaves the IMD system and the electrode at which current enters the IMD system, respectively. Reversing the polarity of the electrodes can be effected by any switching technique known in the art.
A “pulse” is used herein to refer to a single application of electrical charge from the cathode to the cranial nerve. Individual pulses are separated by a time period in which no charge is delivered to the nerve, which can be called the “interpulse interval.” A “burst” is used herein to refer to a plurality of pulses, wherein no charge is delivered to the nerve before the first pulse of the burst for a time period at least twice as long as the interpulse interval and no charge is delivered to the nerve after the last pulse of the burst for a time period at least twice as long as the interpulse interval. The time period between the end of the last pulse of a first burst and the initiation of the first pulse of the next subsequent burst can be called the “interburst interval.” In one embodiment, the interburst interval is at least 100 msec.
A plurality of pulses can refer to any of (a) a number of consecutive pulses within a burst, (b) all the pulses of a burst, or (c) a number of consecutive pulses including the final pulse of a first burst and the first pulse of the next subsequent burst.
Each of the first, second, and third electrical signals can independently contain one or more pulses. In one embodiment, the first electrical signal contains one or more pulses, the second electrical signal contains one or more pulses, and the third electrical signal contains one or more pulses. In a further embodiment, the first electrical signal contains one pulse, the second electrical signal contains one pulse, and the third electrical signal contains one pulse.
The number of pulses contained within the first and second electrical signals or the second and third electrical signals need not be equal, and can be in any ratio. In one embodiment, the ratio is from about 1:100 to about 100:1. In a further embodiment, the ratio is from about 1:10 to about 10:1.
In one embodiment, the first electrical signal contains a first number of pulses, the second electrical signal contains a second number of pulses, and the third electrical signal contains a third number of pulses, wherein the first number of pulses is not equal to the second number of pulses or the second number of pulses is not equal to the third number of pulses.
In another embodiment, the first electrical signal contains one or more bursts, the second electrical signal contains one or more bursts, and the third electrical signal contains one or more bursts. In a further embodiment, the first electrical signal contains one burst, the second electrical signal contains one burst, and the third electrical signal contains one burst.
The number of bursts contained within the first and second electrical signals or the second and third electrical signals need not be equal, and can be in any ratio. In one embodiment, the ratio is from about 1:100 to about 100:1. In a further embodiment, the ratio is from about 1:10 to about 10:1.
In one embodiment, the first electrical signal contains a first number of bursts, the second electrical signal contains a second number of bursts, and the third electrical signal contains a third number of bursts, wherein the first number of bursts is not equal to the second number of bursts or the second number of bursts is not equal to the third number of bursts.
Typical cranial nerve stimulation can be performed with an interpulse frequency of 20-30 Hz (resulting in a number of pulses per burst of 140-1800, at a burst duration from 7-60 sec). In one embodiment, at least one of the first electrical signal, the second electrical signal, and the third electrical signal delivers microbursts. Microburst neurostimulation is discussed by U.S. Ser. No. 11/693,451, filed Mar. 2, 2007 and published as United States patent Publication No. 20070233193, and incorporated herein by reference. In one embodiment, at least one of the first electrical signal, the second electrical signal, and the third electrical signal is characterized by having a number of pulses per microburst from 2 pulses to about 25 pulses, an interpulse interval of about 2 msec to about 50 msec, an interburst period of at least 100 msec, and a microburst duration of less than about 1 sec.
As stated above, different fiber types of cranial nerves propagate action potentials at different velocities. In one embodiment of the method, after performance of a prior applying step, the subsequent applying step is performed before an action potential induced by the prior applying step in C-fibers of the cranial nerve reaches the anode of the subsequent applying step and after an action potential induced by the prior applying step in A-fibers of the cranial nerve has passed the anode of the subsequent applying step. As a result, in this embodiment, an action potential induced in the A-fibers in the prior applying step can propagate along the nerve in the direction from the anode of the prior applying step to the cathode of the prior applying step and beyond to the brain or the distal terminus of the cranial nerve. Whereas, an action potential induced in the C-fibers in the prior applying step, though originally propagating along the nerve in the direction from the anode of the prior applying step to the cathode of the prior applying step, can be blocked by an electrical stimulation performed at the anode of the subsequent applying step, which was the cathode of the prior applying step. To generalize, by performing this method, particular fiber types in the cranial nerve can be selectively stimulated to propagate an action potential to either the proximal terminus (i.e., the brain) or distal terminus of the cranial nerve.
Turning now to
The IMD 200 may comprise a controller 210 capable of controlling various aspects of the operation of the IMD 200. The controller 210 is capable of receiving internal data and/or external data and controlling the generation and delivery of a stimulation signal to target tissues of the patient's body. For example, the controller 210 may receive manual instructions from an operator externally, or may perform stimulation based on internal calculations and programming. The controller 210 is capable of affecting substantially all functions of the IMD 200.
The controller 210 may comprise various components, such as a processor 215, a memory 217, etc. The processor 215 may comprise one or more micro controllers, micro processors, etc., that are capable of executing a variety of software components. The memory 217 may comprise various memory portions, where a number of types of data (e.g., internal data, external data instructions, software codes, status data, diagnostic data, etc.) may be stored. The memory 217 may store various tables or other database content that could be used by the IMD 200 to implement the override of normal operations. The memory 217 may comprise random access memory (RAM) dynamic random access memory (DRAM), electrically erasable programmable read-only memory (EEPROM), flash memory, etc.
The IMD 200 may also comprise a stimulation unit 220. The stimulation unit 220 is capable of generating and delivering a variety of electrical signal therapy signals to one or more electrodes via leads. The stimulation unit 220 is capable of delivering a programmed, primary mode electrical signal to the leads 122 coupled to the IMD 200. The electrical signal may be delivered to the leads 122 by the stimulation unit 220 based upon instructions from the controller 210. The stimulation unit 220 may comprise various types of circuitry, such as stimulation signal generators, impedance control circuitry to control the impedance “seen” by the leads, and other circuitry that receives instructions relating to the type of stimulation to be performed.
The IMD 200 may also comprise an electrode polarity reversal unit 280. The electrode polarity reversal unit 280 is capable of reversing the polarity of electrodes associated with the electrode assembly 125. The electrode polarity reversal unit 280 is shown in more detail in
The IMD 200 may also comprise a power supply 230. The power supply 230 may comprise a battery, voltage regulators, capacitors, etc., to provide power for the operation of the IMD 200, including delivering the stimulation signal. The power supply 230 comprises a power-source battery that in some embodiments may be rechargeable. In other embodiments, a non-rechargeable battery may be used. The power supply 230 provides power for the operation of the IMD 200, including electronic operations and the stimulation function. The power supply 230, may comprise a lithium/thionyl chloride cell or a lithium/carbon monofluoride (LiCFx) cell. Other battery types known in the art of implantable medical devices may also be used.
The IMD 200 also comprises a communication unit 260 capable of facilitating communications between the IMD 200 and various devices. In particular, the communication unit 260 is capable of providing transmission and reception of electronic signals to and from an external unit 270. The external unit 270 may be a device that is capable of programming various modules and stimulation parameters of the IMD 200. In one embodiment, the external unit 270 comprises a computer system that is capable of executing a data-acquisition program. The external unit 270 may be controlled by a healthcare provider, such as a physician, at a base station in, for example, a doctor's office. The external unit 270 may be a computer, preferably a handheld computer or PDA, but may alternatively comprise any other device that is capable of electronic communications and programming. The external unit 270 may download various parameters and program software into the IMD 200 for programming the operation of the implantable device. The external unit 270 may also receive and upload various status conditions and other data from the IMD 200. The communication unit 260 may be hardware, software, firmware, and/or any combination thereof. Communications between the external unit 270 and the communication unit 260 may occur via a wireless or other type of communication, illustrated generally by line 275 in
In one embodiment, the communication unit 260 can transmit a log of stimulation data to the patient, a physician, or another party.
The IMD 200 is capable of delivering stimulation that can be intermittent, periodic, random, sequential, coded, and/or patterned. The stimulation signals may comprise an electrical stimulation frequency of approximately 01 to 2500 Hz. The stimulation signals may comprise a pulse width in the range of approximately 1-2000 micro-seconds. The stimulation signals may comprise current amplitude in the range of approximately 0.1 mA to 10 mA. The stimulation delivered by the IMD 200 according to its programming may be referred to herein as “normal operations” or as a “normal operating mode.”
The IMD 200 may also comprise a magnetic field detection unit 290. The magnetic field detection unit 290 is capable of detecting magnetic and/or electromagnetic fields of a predetermined magnitude. Whether the magnetic field results from a magnet placed proximate to the IMD 200, or whether it results from a substantial magnetic field encompassing an area, the magnetic field detection unit 290 is capable of informing the IMD of the existence of a magnetic field. The changeable electrode polarity stimulation described herein may be activated, deactivated, or alternatively activated or deactivated using a magnetic input.
The magnetic field detection unit 290 may comprise various sensors, such as a Reed Switch circuitry, a Hall Effect sensor circuitry, and/or the like. The magnetic field detection unit 290 may also comprise various registers and/or data transceiver circuits that are capable of sending signals that are indicative of various magnetic fields, the time period of such fields, etc. In this manner, the magnetic field detection unit 290 is capable of detecting whether the detected magnetic field relates to an inhibitory input or an excitory input from an external source. The inhibitory input may refer to an inhibition of, or a deviation from, normal stimulation operation. The excitory input may refer to additional stimulation or deviation from normal stimulation.
One or more of the blocks illustrated in the block diagram of the IMD 200 in
Instructions for implementing a series of predetermined and/or programmable stimulation regimens may be stored in the IMD 200. These stimulation regimens may include data relating to the type of bidirectional stimulation to be implemented. For example, a first stimulation regimen may call for a particular type of pulse signal in one direction and having one electrode polarity configuration (e.g., an electrical signal in which action potentials to the brain are not blocked, and in which action potentials to a distal terminus of the nerve are partially or completely blocked or inhibited), followed by a plurality of microburst type signals during the normal off-time and delivered in the other direction (e.g., with the electrode polarities reversed such that action potentials to the brain are partially or completely blocked or inhibited, but action potentials to the distal terminus of the nerve are not blocked or inhibited). A second exemplary stimulation regimen may call for a series of pulses in a first direction, followed by an off-time, and then followed by a series of pulses in the opposite direction. A third exemplary stimulation regimen may call for switching electrode polarity in a 2-electrode configuration after each pulse, such that propagation of action potentials in each direction are sequentially permitted and then at least partially blocked, then permitted again in alternating sequence. In other embodiments, multiple pulses may be generated in a first electrode configuration, followed by switching electrode polarity to a second electrode configuration for one or a few pulses, followed by switching polarity back to the first electrode configuration. Information relating to the stimulation regimens may be used by the electrode polarity reversal unit 280 to control the operations of the first through nth switches 330(1-n).
In one embodiment, each of a plurality of stimulation regimens may respectively relate to a particular disorder. In one embodiment, different regimens relating to the same disorder may be implemented to accommodate improvements or regressions in the patient's present condition relative to his or her condition at previous times. By providing flexibility in electrode configurations nearly instantaneously, the present invention greatly expands the range of adjustments that may be made to respond to changes in the patient's underlying medical condition.
The switching controller 345 may be a processor that is capable of receiving data relating to the stimulation regimens. In an alternative embodiment, the switching controller may be a software or a firmware module. Based upon the particulars of the stimulation regimens, the switching timing unit 333 may provide timing data to the switching controller 345. The first through nth switches 330(1-n) may be electrical devices, electromechanical devices, and/or solid state devices (e.g., transistors).
However, if the signal is received, the IMD 200 then implements a changeable electrode polarity stimulation mode shown in steps 430-460. Specifically, the IMD 200 delivers 430 a first predetermined number of pulses in a first polarity configuration of the electrodes. For an example, a first electrode 125(1) may be the cathode and a second electrode 125(2) may be the anode in step 430. After the first predetermined number of pulses are delivered in the first configuration (step 430), the IMD 200 reverses 440 the polarity of the electrodes to a second polarity configuration. Continuing the example, the first electrode 125(1) may be switched to be the anode and the second electrode 125(2) may be switched to be the cathode. It will be appreciated that, where 3 or more electrodes are used, only some of the electrode polarities may be reversed. Step 450 resembles step 430, though it will be noted the second electrode polarity configuration differs from the first electrode polarity configuration, and the second predetermined number of pulses may differ in number of pulses or other stimulation parameters (pulse frequency, pulse width, On Time, Off Time, interpulse interval, number of pulses per burst, or interburst interval, among others) from the first predetermined number of pulses. Step 460 resembles step 440, though it will be noted it reverts the configuration of the electrodes to the first electrode polarity configuration as in step 430.
After steps 430-460 have been performed, the IMD 200 checks 470 whether a signal to discontinue the changeable electrode polarity stimulation mode has been received. The signal to discontinue the changeable electrode polarity stimulation mode can be received from the same sources described above in the context of checking step 420. Regardless of the nature of the signal, if the IMD 200 does not detect the signal when performing checking step 470, the IMD 200 continues changeable electrode polarity stimulation by returning to step 430. If the signal is detected when performing checking step 470, the IMD 200 reverts to single polarity stimulation 410.
In the methods shown in
The particular embodiments disclosed above are illustrative only as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown other than as described in the claims below. It is, therefore, evident that the particular embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the invention. Accordingly, the protection sought herein is as set forth in the claims below.
This application is a Continuation-in-Part of U.S. patent application No. 11/046,430 filed on Jan. 28, 2005 with inventors Randolph K. Armstrong and Scott A. Armstrong.
Number | Name | Date | Kind |
---|---|---|---|
3760812 | Timm et al. | Sep 1973 | A |
3796221 | Hagfors | Mar 1974 | A |
4107469 | Jenkins | Aug 1978 | A |
4305402 | Katims | Dec 1981 | A |
4338945 | Kosugi et al. | Jul 1982 | A |
4424812 | Lesnick | Jan 1984 | A |
4431000 | Butler et al. | Feb 1984 | A |
4459989 | Borkan | Jul 1984 | A |
4503863 | Katims | Mar 1985 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4573481 | Bullara | Mar 1986 | A |
4577316 | Schiff | Mar 1986 | A |
4590946 | Loeb | May 1986 | A |
4592339 | Kuzmak et al. | Jun 1986 | A |
4606349 | Livingston et al. | Aug 1986 | A |
4608985 | Crish et al. | Sep 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4625308 | Kim et al. | Nov 1986 | A |
4628942 | Sweeney et al. | Dec 1986 | A |
4649936 | Ungar et al. | Mar 1987 | A |
4702254 | Zarbara | Oct 1987 | A |
4793353 | Borkan | Dec 1988 | A |
4867164 | Zabara | Sep 1989 | A |
4920979 | Bullara | May 1990 | A |
4949721 | Toriu et al. | Aug 1990 | A |
4977895 | Tannenbaum | Dec 1990 | A |
4979511 | Terry, Jr. | Dec 1990 | A |
5025807 | Zabara | Jun 1991 | A |
5081987 | Nigam | Jan 1992 | A |
5154172 | Terry, Jr. et al. | Oct 1992 | A |
5179950 | Stanislaw | Jan 1993 | A |
5186170 | Varrichio et al. | Feb 1993 | A |
5188104 | Wernicke et al. | Feb 1993 | A |
5205285 | Baker, Jr. | Apr 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5222494 | Baker, Jr. | Jun 1993 | A |
5231988 | Wernicke et al. | Aug 1993 | A |
5235980 | Varrichio et al. | Aug 1993 | A |
5263480 | Wernicke et al. | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5330507 | Schwartz | Jul 1994 | A |
5330515 | Rutecki et al. | Jul 1994 | A |
5334221 | Bardy | Aug 1994 | A |
5335657 | Terry, Jr. et al. | Aug 1994 | A |
5354320 | Schaldach et al. | Oct 1994 | A |
5411531 | Hill et al. | May 1995 | A |
5411540 | Edell et al. | May 1995 | A |
5423872 | Cigaina | Jun 1995 | A |
5507784 | Hill et al. | Apr 1996 | A |
5522862 | Testerman et al. | Jun 1996 | A |
5522865 | Schulman et al. | Jun 1996 | A |
5531778 | Maschino et al. | Jul 1996 | A |
5540730 | Terry, Jr. et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5571150 | Wernicke et al. | Nov 1996 | A |
5601617 | Loeb et al. | Feb 1997 | A |
5611350 | John | Mar 1997 | A |
5645570 | Corbucci | Jul 1997 | A |
5651378 | Matheny et al. | Jul 1997 | A |
5658318 | Stroetmann et al. | Aug 1997 | A |
5690681 | Geddes et al. | Nov 1997 | A |
5690688 | Noren et al. | Nov 1997 | A |
5690691 | Chen et al. | Nov 1997 | A |
5700282 | Zabara | Dec 1997 | A |
5702428 | Tippey et al. | Dec 1997 | A |
5702429 | King | Dec 1997 | A |
5707400 | Terry, Jr. et al. | Jan 1998 | A |
5755750 | Petruska et al. | May 1998 | A |
5792212 | Weijand | Aug 1998 | A |
5800474 | Benabid et al. | Sep 1998 | A |
5814092 | King | Sep 1998 | A |
5836994 | Bourgeois | Nov 1998 | A |
5861014 | Familoni | Jan 1999 | A |
5913882 | King | Jun 1999 | A |
5916239 | Geddes et al. | Jun 1999 | A |
5928272 | Adkins et al. | Jul 1999 | A |
5941906 | Barreras, Sr. et al. | Aug 1999 | A |
5995868 | Osorio et al. | Nov 1999 | A |
6002966 | Loeb et al. | Dec 1999 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6041258 | Cigaina et al. | Mar 2000 | A |
6083249 | Familoni | Jul 2000 | A |
6101412 | Duhaylongsod | Aug 2000 | A |
6104955 | Bourgeois | Aug 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6115628 | Stadler et al. | Sep 2000 | A |
6132361 | Epstein et al. | Oct 2000 | A |
6141590 | Renirie et al. | Oct 2000 | A |
6161044 | Silverstone | Dec 2000 | A |
6167311 | Rezai | Dec 2000 | A |
6175764 | Loeb et al. | Jan 2001 | B1 |
6188929 | Giordano | Feb 2001 | B1 |
6219580 | Faltys et al. | Apr 2001 | B1 |
6221908 | Kilgard et al. | Apr 2001 | B1 |
6238423 | Bardy | May 2001 | B1 |
6249704 | Maltan et al. | Jun 2001 | B1 |
6253109 | Gielen | Jun 2001 | B1 |
6266564 | Hill et al. | Jul 2001 | B1 |
6269270 | Boveja | Jul 2001 | B1 |
6295472 | Rubinstein et al. | Sep 2001 | B1 |
6304775 | Iasemidis et al. | Oct 2001 | B1 |
6308102 | Sieracki | Oct 2001 | B1 |
6324421 | Stadler et al. | Nov 2001 | B1 |
6327503 | Familoni | Dec 2001 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6341236 | Osorio et al. | Jan 2002 | B1 |
6353762 | Baudino et al. | Mar 2002 | B1 |
6356788 | Boveja | Mar 2002 | B2 |
6358203 | Bardy | Mar 2002 | B2 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6366814 | Boveja | Apr 2002 | B1 |
6374140 | Rise | Apr 2002 | B1 |
6381493 | Stadler et al. | Apr 2002 | B1 |
6381496 | Meadows et al. | Apr 2002 | B1 |
6381499 | Taylor et al. | Apr 2002 | B1 |
6418344 | Rezai et al. | Jul 2002 | B1 |
6425852 | Epstein et al. | Jul 2002 | B1 |
6438423 | Rezai et al. | Aug 2002 | B1 |
6449512 | Boveja | Sep 2002 | B1 |
6453199 | Kobozev | Sep 2002 | B1 |
6459936 | Fischell et al. | Oct 2002 | B2 |
6463328 | John | Oct 2002 | B1 |
6466822 | Pless | Oct 2002 | B1 |
6473639 | Fischell et al. | Oct 2002 | B1 |
6473644 | Terry, Jr. et al. | Oct 2002 | B1 |
6477417 | Levine | Nov 2002 | B1 |
6477418 | Plicchi et al. | Nov 2002 | B2 |
6480743 | Kirkpatrick et al. | Nov 2002 | B1 |
6484132 | Hively et al. | Nov 2002 | B1 |
6487446 | Hill et al. | Nov 2002 | B1 |
6505074 | Boveja et al. | Jan 2003 | B2 |
6522928 | Whitehurst et al. | Feb 2003 | B2 |
6532388 | Hill et al. | Mar 2003 | B1 |
6549804 | Osorio et al. | Apr 2003 | B1 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6564102 | Boveja | May 2003 | B1 |
6565503 | Leysieffer et al. | May 2003 | B2 |
6579280 | Kovach et al. | Jun 2003 | B1 |
6587719 | Barrett et al. | Jul 2003 | B1 |
6587724 | Mann | Jul 2003 | B2 |
6587726 | Lurie et al. | Jul 2003 | B2 |
6587727 | Osorio et al. | Jul 2003 | B2 |
6591138 | Fischell et al. | Jul 2003 | B1 |
6594524 | Esteller et al. | Jul 2003 | B2 |
6600953 | Flesler et al. | Jul 2003 | B2 |
6609025 | Barrett et al. | Aug 2003 | B2 |
6609030 | Rezai et al. | Aug 2003 | B1 |
6609031 | Law et al. | Aug 2003 | B1 |
6610713 | Tracey | Aug 2003 | B2 |
6611715 | Boveja | Aug 2003 | B1 |
6612983 | Marchal | Sep 2003 | B1 |
6615081 | Boveja | Sep 2003 | B1 |
6615084 | Cigaina | Sep 2003 | B1 |
6615085 | Boveja | Sep 2003 | B1 |
6622038 | Barrett et al. | Sep 2003 | B2 |
6622041 | Terry, Jr. et al. | Sep 2003 | B2 |
6622047 | Barrett et al. | Sep 2003 | B2 |
6628987 | Hill et al. | Sep 2003 | B1 |
6656960 | Puskas | Dec 2003 | B2 |
6662053 | Borkan | Dec 2003 | B2 |
6668191 | Boveja | Dec 2003 | B1 |
6671547 | Lyster et al. | Dec 2003 | B2 |
6671555 | Gielen et al. | Dec 2003 | B2 |
6671556 | Osorio et al. | Dec 2003 | B2 |
6684104 | Gordon et al. | Jan 2004 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6690973 | Hill et al. | Feb 2004 | B2 |
6690974 | Archer et al. | Feb 2004 | B2 |
6708064 | Rezai | Mar 2004 | B2 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6731979 | MacDonald | May 2004 | B2 |
6731986 | Mann | May 2004 | B2 |
6754536 | Swoyer et al. | Jun 2004 | B2 |
6760626 | Boveja | Jul 2004 | B1 |
6764498 | Mische | Jul 2004 | B2 |
6768969 | Nikitin et al. | Jul 2004 | B1 |
6775573 | Schuler et al. | Aug 2004 | B2 |
6793670 | Osorio et al. | Sep 2004 | B2 |
6819956 | DiLorenzo | Nov 2004 | B2 |
6826428 | Chen et al. | Nov 2004 | B1 |
6832114 | Whitehurst et al. | Dec 2004 | B1 |
6853862 | Marchal et al. | Feb 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6895278 | Gordon | May 2005 | B1 |
6904390 | Nikitin et al. | Jun 2005 | B2 |
6907295 | Gross et al. | Jun 2005 | B2 |
6920357 | Osorio et al. | Jul 2005 | B2 |
6934580 | Osorio et al. | Aug 2005 | B1 |
6944501 | Pless | Sep 2005 | B1 |
6961618 | Osorio et al. | Nov 2005 | B2 |
7006859 | Osorio et al. | Feb 2006 | B1 |
7006872 | Gielen et al. | Feb 2006 | B2 |
7050856 | Stypulkowski | May 2006 | B2 |
7054686 | MacDonald | May 2006 | B2 |
7146217 | Firlik et al. | Dec 2006 | B2 |
7167750 | Knudson et al. | Jan 2007 | B2 |
7177678 | Osorio et al. | Feb 2007 | B1 |
7188053 | Nikitin et al. | Mar 2007 | B2 |
7204833 | Osorio et al. | Apr 2007 | B1 |
7209787 | DiLorenzo | Apr 2007 | B2 |
7231254 | DiLorenzo | Jun 2007 | B2 |
7236830 | Gliner | Jun 2007 | B2 |
7236831 | Firlik et al. | Jun 2007 | B2 |
7242983 | Frei et al. | Jul 2007 | B2 |
7242984 | DiLorenzo | Jul 2007 | B2 |
7340302 | Falkenberg et al. | Mar 2008 | B1 |
20010034541 | Lyden | Oct 2001 | A1 |
20010037220 | Merry et al. | Nov 2001 | A1 |
20020052539 | Haller et al. | May 2002 | A1 |
20020065509 | Lebel et al. | May 2002 | A1 |
20020072782 | Osorio et al. | Jun 2002 | A1 |
20020082480 | Riff et al. | Jun 2002 | A1 |
20020099412 | Fischell et al. | Jul 2002 | A1 |
20020099417 | Naritoku et al. | Jul 2002 | A1 |
20020116030 | Rezai | Aug 2002 | A1 |
20020120310 | Linden et al. | Aug 2002 | A1 |
20020133204 | Hrdlicka | Sep 2002 | A1 |
20020143368 | Bakels et al. | Oct 2002 | A1 |
20020151939 | Rezai | Oct 2002 | A1 |
20020153901 | Davis et al. | Oct 2002 | A1 |
20020188214 | Misczynski et al. | Dec 2002 | A1 |
20030028226 | Thompson et al. | Feb 2003 | A1 |
20030055457 | MacDonald | Mar 2003 | A1 |
20030074032 | Gliner | Apr 2003 | A1 |
20030083716 | Nicolelis et al. | May 2003 | A1 |
20030088274 | Gliner et al. | May 2003 | A1 |
20030095648 | Kaib et al. | May 2003 | A1 |
20030097161 | Firlik et al. | May 2003 | A1 |
20030109903 | Berrang et al. | Jun 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030130706 | Sheffield et al. | Jul 2003 | A1 |
20030144711 | Pless et al. | Jul 2003 | A1 |
20030144829 | Geatz et al. | Jul 2003 | A1 |
20030181954 | Rezai | Sep 2003 | A1 |
20030181958 | Dobak | Sep 2003 | A1 |
20030181959 | Dobak | Sep 2003 | A1 |
20030208212 | Cigaina | Nov 2003 | A1 |
20030210147 | Humbard | Nov 2003 | A1 |
20030212440 | Boveja | Nov 2003 | A1 |
20030236558 | Whitehurst et al. | Dec 2003 | A1 |
20040006278 | Webb et al. | Jan 2004 | A1 |
20040015205 | Whitehurst et al. | Jan 2004 | A1 |
20040036377 | Mezinis | Feb 2004 | A1 |
20040039424 | Merritt et al. | Feb 2004 | A1 |
20040088024 | Firlik et al. | May 2004 | A1 |
20040111139 | McCreery | Jun 2004 | A1 |
20040112894 | Varma | Jun 2004 | A1 |
20040122484 | Hatlestad et al. | Jun 2004 | A1 |
20040122485 | Stahmann et al. | Jun 2004 | A1 |
20040122489 | Mazar et al. | Jun 2004 | A1 |
20040133119 | Osorio et al. | Jul 2004 | A1 |
20040138516 | Osorio et al. | Jul 2004 | A1 |
20040138517 | Osorio et al. | Jul 2004 | A1 |
20040138518 | Rise et al. | Jul 2004 | A1 |
20040138647 | Osorio et al. | Jul 2004 | A1 |
20040138711 | Osorio et al. | Jul 2004 | A1 |
20040147969 | Mann et al. | Jul 2004 | A1 |
20040147992 | Bluger et al. | Jul 2004 | A1 |
20040153129 | Pless et al. | Aug 2004 | A1 |
20040158119 | Osorio et al. | Aug 2004 | A1 |
20040158165 | Yonce et al. | Aug 2004 | A1 |
20040167583 | Knudson et al. | Aug 2004 | A1 |
20040167587 | Thompson | Aug 2004 | A1 |
20040172085 | Knudson et al. | Sep 2004 | A1 |
20040172088 | Knudson et al. | Sep 2004 | A1 |
20040172089 | Whitehurst et al. | Sep 2004 | A1 |
20040172091 | Rezai | Sep 2004 | A1 |
20040172094 | Cohen et al. | Sep 2004 | A1 |
20040176812 | Knudson et al. | Sep 2004 | A1 |
20040176831 | Gliner et al. | Sep 2004 | A1 |
20040193231 | David et al. | Sep 2004 | A1 |
20040199146 | Rogers et al. | Oct 2004 | A1 |
20040199187 | Loughran | Oct 2004 | A1 |
20040199212 | Fischell et al. | Oct 2004 | A1 |
20040210270 | Erickson | Oct 2004 | A1 |
20040210274 | Bauhahn et al. | Oct 2004 | A1 |
20040249302 | Donoghue et al. | Dec 2004 | A1 |
20040249416 | Yun et al. | Dec 2004 | A1 |
20040260346 | Overall et al. | Dec 2004 | A1 |
20040263172 | Gray et al. | Dec 2004 | A1 |
20050004615 | Sanders | Jan 2005 | A1 |
20050004621 | Boveja et al. | Jan 2005 | A1 |
20050010262 | Rezai et al. | Jan 2005 | A1 |
20050015128 | Rezai et al. | Jan 2005 | A1 |
20050016657 | Bluger | Jan 2005 | A1 |
20050020887 | Goldberg | Jan 2005 | A1 |
20050021092 | Yun et al. | Jan 2005 | A1 |
20050021103 | DiLorenzo | Jan 2005 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050021105 | Firlik et al. | Jan 2005 | A1 |
20050021106 | Firlik et al. | Jan 2005 | A1 |
20050021107 | Firlik et al. | Jan 2005 | A1 |
20050021118 | Genau et al. | Jan 2005 | A1 |
20050027284 | Lozano et al. | Feb 2005 | A1 |
20050028026 | Shirley et al. | Feb 2005 | A1 |
20050033378 | Sheffield et al. | Feb 2005 | A1 |
20050033379 | Lozano et al. | Feb 2005 | A1 |
20050038326 | Mathur | Feb 2005 | A1 |
20050038484 | Knudson et al. | Feb 2005 | A1 |
20050049515 | Misczynski et al. | Mar 2005 | A1 |
20050049655 | Boveja et al. | Mar 2005 | A1 |
20050060007 | Goetz | Mar 2005 | A1 |
20050060008 | Goetz | Mar 2005 | A1 |
20050060009 | Goetz | Mar 2005 | A1 |
20050060010 | Goetz | Mar 2005 | A1 |
20050065562 | Rezai | Mar 2005 | A1 |
20050065573 | Rezai | Mar 2005 | A1 |
20050065574 | Rezai | Mar 2005 | A1 |
20050065575 | Dobak | Mar 2005 | A1 |
20050070971 | Fowler et al. | Mar 2005 | A1 |
20050075679 | Gliner et al. | Apr 2005 | A1 |
20050075680 | Lowry et al. | Apr 2005 | A1 |
20050075681 | Rezai et al. | Apr 2005 | A1 |
20050075691 | Phillips et al. | Apr 2005 | A1 |
20050075701 | Shafer | Apr 2005 | A1 |
20050075702 | Shafer | Apr 2005 | A1 |
20050088145 | Loch | Apr 2005 | A1 |
20050101873 | Misczynski et al. | May 2005 | A1 |
20050102002 | Salo et al. | May 2005 | A1 |
20050107753 | Rezai et al. | May 2005 | A1 |
20050107842 | Rezai | May 2005 | A1 |
20050107858 | Bluger | May 2005 | A1 |
20050113705 | Fischell et al. | May 2005 | A1 |
20050113744 | Donoghue et al. | May 2005 | A1 |
20050119703 | DiLorenzo | Jun 2005 | A1 |
20050124901 | Misczynski et al. | Jun 2005 | A1 |
20050131467 | Boveja et al. | Jun 2005 | A1 |
20050131485 | Knudson et al. | Jun 2005 | A1 |
20050131486 | Boveja et al. | Jun 2005 | A1 |
20050131493 | Boveja et al. | Jun 2005 | A1 |
20050131506 | Rezai et al. | Jun 2005 | A1 |
20050137480 | Alt et al. | Jun 2005 | A1 |
20050143781 | Carbunaru et al. | Jun 2005 | A1 |
20050143786 | Boveja | Jun 2005 | A1 |
20050148893 | Misczynski et al. | Jul 2005 | A1 |
20050148894 | Misczynski et al. | Jul 2005 | A1 |
20050148895 | Misczynski et al. | Jul 2005 | A1 |
20050153885 | Yun et al. | Jul 2005 | A1 |
20050154425 | Boveja et al. | Jul 2005 | A1 |
20050154435 | Stern et al. | Jul 2005 | A1 |
20050159789 | Brockway et al. | Jul 2005 | A1 |
20050161052 | Rezai et al. | Jul 2005 | A1 |
20050165458 | Boveja et al. | Jul 2005 | A1 |
20050177192 | Rezai et al. | Aug 2005 | A1 |
20050177200 | George et al. | Aug 2005 | A1 |
20050177206 | North et al. | Aug 2005 | A1 |
20050182389 | LaPorte et al. | Aug 2005 | A1 |
20050187590 | Boveja et al. | Aug 2005 | A1 |
20050187593 | Housworth et al. | Aug 2005 | A1 |
20050187796 | Rosenfeld et al. | Aug 2005 | A1 |
20050192644 | Boveja et al. | Sep 2005 | A1 |
20050197590 | Osorio et al. | Sep 2005 | A1 |
20050222631 | Dalal et al. | Oct 2005 | A1 |
20050228693 | Webb et al. | Oct 2005 | A1 |
20050240246 | Lee et al. | Oct 2005 | A1 |
20050245944 | Rezai | Nov 2005 | A1 |
20050245971 | Brockway et al. | Nov 2005 | A1 |
20050245990 | Roberson | Nov 2005 | A1 |
20050261542 | Riehl | Nov 2005 | A1 |
20050267550 | Hess et al. | Dec 2005 | A1 |
20050272280 | Osypka | Dec 2005 | A1 |
20050277872 | Colby, Jr. et al. | Dec 2005 | A1 |
20050277998 | Tracey et al. | Dec 2005 | A1 |
20050283200 | Rezai et al. | Dec 2005 | A1 |
20050283201 | Machado et al. | Dec 2005 | A1 |
20050283208 | Von Arx et al. | Dec 2005 | A1 |
20050288600 | Zhang et al. | Dec 2005 | A1 |
20050288736 | Persen et al. | Dec 2005 | A1 |
20050288760 | Machado et al. | Dec 2005 | A1 |
20060009815 | Boveja | Jan 2006 | A1 |
20060015153 | Gliner et al. | Jan 2006 | A1 |
20060020292 | Goetz et al. | Jan 2006 | A1 |
20060020491 | Mongeon et al. | Jan 2006 | A1 |
20060041222 | Dewing et al. | Feb 2006 | A1 |
20060041223 | Dewing et al. | Feb 2006 | A1 |
20060041287 | Dewing et al. | Feb 2006 | A1 |
20060047205 | Ludomirsky et al. | Mar 2006 | A1 |
20060052843 | Elsner et al. | Mar 2006 | A1 |
20060058597 | Machado et al. | Mar 2006 | A1 |
20060064133 | Von Arx et al. | Mar 2006 | A1 |
20060064134 | Mazar et al. | Mar 2006 | A1 |
20060064143 | Von Arx et al. | Mar 2006 | A1 |
20060069322 | Zhang et al. | Mar 2006 | A1 |
20060074450 | Boveja | Apr 2006 | A1 |
20060079936 | Boveja | Apr 2006 | A1 |
20060079942 | Deno et al. | Apr 2006 | A1 |
20060079945 | Libbus | Apr 2006 | A1 |
20060085046 | Rezai et al. | Apr 2006 | A1 |
20060094971 | Drew | May 2006 | A1 |
20060095081 | Zhou et al. | May 2006 | A1 |
20060100667 | Machado et al. | May 2006 | A1 |
20060106430 | Fowler et al. | May 2006 | A1 |
20060106431 | Wyler et al. | May 2006 | A1 |
20060111644 | Guttag et al. | May 2006 | A1 |
20060122525 | Shusterman | Jun 2006 | A1 |
20060122667 | Chavan et al. | Jun 2006 | A1 |
20060122864 | Gottesman et al. | Jun 2006 | A1 |
20060135877 | Giftakis et al. | Jun 2006 | A1 |
20060135881 | Giftakis et al. | Jun 2006 | A1 |
20060155495 | Osorio et al. | Jul 2006 | A1 |
20060161459 | Rosenfeld et al. | Jul 2006 | A9 |
20060167497 | Armstrong et al. | Jul 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060173522 | Osorio | Aug 2006 | A1 |
20060190056 | Fowler et al. | Aug 2006 | A1 |
20060195155 | Firlik et al. | Aug 2006 | A1 |
20060195163 | KenKnight et al. | Aug 2006 | A1 |
20060200206 | Firlik et al. | Sep 2006 | A1 |
20060212091 | Lozano et al. | Sep 2006 | A1 |
20060217780 | Gliner et al. | Sep 2006 | A1 |
20060220839 | Fifolt et al. | Oct 2006 | A1 |
20060224067 | Giftakis et al. | Oct 2006 | A1 |
20060224191 | DiLorenzo | Oct 2006 | A1 |
20060241697 | Libbus et al. | Oct 2006 | A1 |
20060241725 | Libbus et al. | Oct 2006 | A1 |
20060253164 | Zhang et al. | Nov 2006 | A1 |
20060253168 | Wyler et al. | Nov 2006 | A1 |
20060253169 | Wyler et al. | Nov 2006 | A1 |
20060253170 | Wyler et al. | Nov 2006 | A1 |
20060253171 | Wyler et al. | Nov 2006 | A1 |
20060259095 | Wyler et al. | Nov 2006 | A1 |
20060264730 | Stivoric et al. | Nov 2006 | A1 |
20060265018 | Smith et al. | Nov 2006 | A1 |
20060271409 | Rosenfeld et al. | Nov 2006 | A1 |
20060293720 | DiLorenzo | Dec 2006 | A1 |
20070027486 | Armstrong et al. | Feb 2007 | A1 |
20070032734 | Najafi et al. | Feb 2007 | A1 |
20070032834 | Gliner et al. | Feb 2007 | A1 |
20070038262 | Kieval et al. | Feb 2007 | A1 |
20070043392 | Gliner et al. | Feb 2007 | A1 |
20070055320 | Weinand et al. | Mar 2007 | A1 |
20070073150 | Gopalsami et al. | Mar 2007 | A1 |
20070073346 | Corbucci et al. | Mar 2007 | A1 |
20070073355 | DiLorenzo | Mar 2007 | A1 |
20070078491 | Siejko et al. | Apr 2007 | A1 |
20070088403 | Wyler et al. | Apr 2007 | A1 |
20070088404 | Wyler et al. | Apr 2007 | A1 |
20070088405 | Jacobson et al. | Apr 2007 | A1 |
20070100278 | Frei et al. | May 2007 | A1 |
20070100397 | Seeberger et al. | May 2007 | A1 |
20070100398 | Sloan | May 2007 | A1 |
20070112393 | Gliner et al. | May 2007 | A1 |
20070123946 | Masoud | May 2007 | A1 |
20070135855 | Foshee et al. | Jun 2007 | A1 |
20070142862 | DiLorenzo | Jun 2007 | A1 |
20070142873 | Esteller et al. | Jun 2007 | A1 |
20070149952 | Bland et al. | Jun 2007 | A1 |
20070150011 | Meyer et al. | Jun 2007 | A1 |
20070150014 | Kramer et al. | Jun 2007 | A1 |
20070150024 | Leyde et al. | Jun 2007 | A1 |
20070150025 | DiLorenzo et al. | Jun 2007 | A1 |
20070156179 | Karashurov | Jul 2007 | A1 |
20070156450 | Roehm et al. | Jul 2007 | A1 |
20070156626 | Roehm et al. | Jul 2007 | A1 |
20070161919 | DiLorenzo | Jul 2007 | A1 |
20070162086 | DiLorenzo | Jul 2007 | A1 |
20070167991 | DiLorenzo | Jul 2007 | A1 |
20070173901 | Reeve | Jul 2007 | A1 |
20070179534 | Firlik et al. | Aug 2007 | A1 |
20070179558 | Gliner et al. | Aug 2007 | A1 |
20070179584 | Gliner | Aug 2007 | A1 |
20070191905 | Errico et al. | Aug 2007 | A1 |
20070203548 | Pawelzik et al. | Aug 2007 | A1 |
20070208212 | DiLorenzo | Sep 2007 | A1 |
20070208390 | Von Arx et al. | Sep 2007 | A1 |
20070213785 | Osorio et al. | Sep 2007 | A1 |
20070233192 | Craig | Oct 2007 | A1 |
20070233193 | Craig | Oct 2007 | A1 |
20070238939 | Giftakis et al. | Oct 2007 | A1 |
20070239210 | Libbus et al. | Oct 2007 | A1 |
20070239211 | Lorincz et al. | Oct 2007 | A1 |
20070239220 | Greenhut et al. | Oct 2007 | A1 |
20070244407 | Osorio | Oct 2007 | A1 |
20070249953 | Frei et al. | Oct 2007 | A1 |
20070249954 | Virag et al. | Oct 2007 | A1 |
20070250130 | Ball et al. | Oct 2007 | A1 |
20070250145 | Kraus et al. | Oct 2007 | A1 |
20070255147 | Drew et al. | Nov 2007 | A1 |
20070255155 | Drew et al. | Nov 2007 | A1 |
20070255330 | Lee et al. | Nov 2007 | A1 |
20070255337 | Lu | Nov 2007 | A1 |
20070260147 | Giftakis et al. | Nov 2007 | A1 |
20070260289 | Giftakis et al. | Nov 2007 | A1 |
20070265489 | Fowler et al. | Nov 2007 | A1 |
20070265508 | Sheikhzadeh-Nadjar et al. | Nov 2007 | A1 |
20070265536 | Giftakis et al. | Nov 2007 | A1 |
20070272260 | Nikitin et al. | Nov 2007 | A1 |
20070282177 | Pilz | Dec 2007 | A1 |
20070287931 | Dilorenzo | Dec 2007 | A1 |
20070288072 | Pascual-Leone et al. | Dec 2007 | A1 |
20070299349 | Alt et al. | Dec 2007 | A1 |
20070299473 | Matos | Dec 2007 | A1 |
20070299480 | Hill | Dec 2007 | A1 |
20080015651 | Ettori et al. | Jan 2008 | A1 |
20080015652 | Maile et al. | Jan 2008 | A1 |
20080021332 | Brainard, III | Jan 2008 | A1 |
20080021341 | Harris et al. | Jan 2008 | A1 |
20080021517 | Dietrich | Jan 2008 | A1 |
20080021520 | Dietrich | Jan 2008 | A1 |
20080027347 | Harris et al. | Jan 2008 | A1 |
20080027348 | Harris et al. | Jan 2008 | A1 |
20080027515 | Harris et al. | Jan 2008 | A1 |
20080033502 | Harris et al. | Feb 2008 | A1 |
20080033503 | Fowler et al. | Feb 2008 | A1 |
20080033508 | Frei et al. | Feb 2008 | A1 |
20080039895 | Fowler et al. | Feb 2008 | A1 |
20080046035 | Fowler et al. | Feb 2008 | A1 |
20080046037 | Haubrich et al. | Feb 2008 | A1 |
20080046038 | Hill et al. | Feb 2008 | A1 |
20080051852 | Dietrich et al. | Feb 2008 | A1 |
20080058884 | Matos | Mar 2008 | A1 |
20080064934 | Frei et al. | Mar 2008 | A1 |
20080071323 | Lowry et al. | Mar 2008 | A1 |
20080077028 | Schaldach et al. | Mar 2008 | A1 |
20080081962 | Miller et al. | Apr 2008 | A1 |
20080082132 | Annest et al. | Apr 2008 | A1 |
20080103548 | Fowler et al. | May 2008 | A1 |
20080114417 | Leyde | May 2008 | A1 |
20080119900 | DiLorenzo | May 2008 | A1 |
20080125820 | Stahmann et al. | May 2008 | A1 |
20080139870 | Gliner et al. | Jun 2008 | A1 |
20080146890 | LeBoeuf et al. | Jun 2008 | A1 |
20080146959 | Sheffield et al. | Jun 2008 | A1 |
20080161712 | Leyde | Jul 2008 | A1 |
20080161713 | Leyde et al. | Jul 2008 | A1 |
20080161879 | Firlik et al. | Jul 2008 | A1 |
20080161880 | Firlik et al. | Jul 2008 | A1 |
20080161881 | Firlik et al. | Jul 2008 | A1 |
20080161882 | Firlik et al. | Jul 2008 | A1 |
20080183096 | Snyder et al. | Jul 2008 | A1 |
20080183097 | Leyde et al. | Jul 2008 | A1 |
20080183245 | Van Oort et al. | Jul 2008 | A1 |
20080195175 | Balzer et al. | Aug 2008 | A1 |
20080200925 | Johnson | Aug 2008 | A1 |
20080208013 | Zhang et al. | Aug 2008 | A1 |
20080208074 | Snyder et al. | Aug 2008 | A1 |
20080208285 | Fowler et al. | Aug 2008 | A1 |
20080208291 | Leyde et al. | Aug 2008 | A1 |
20080208781 | Snyder | Aug 2008 | A1 |
20080215112 | Firlik et al. | Sep 2008 | A1 |
20080215114 | Stuerzinger et al. | Sep 2008 | A1 |
20080221644 | Vallapureddy et al. | Sep 2008 | A1 |
20080234598 | Snyder et al. | Sep 2008 | A1 |
20080249591 | Gaw et al. | Oct 2008 | A1 |
20080255582 | Harris | Oct 2008 | A1 |
20090054795 | Misczynski et al. | Feb 2009 | A1 |
20090076567 | Fowler et al. | Mar 2009 | A1 |
Number | Date | Country |
---|---|---|
2339971 | Jun 2004 | CA |
0402683 | Dec 1990 | EP |
0713714 | May 1996 | EP |
1139861 | Dec 1999 | EP |
1070518 | Jan 2001 | EP |
0944411 | Apr 2001 | EP |
1145736 | Oct 2001 | EP |
1483020 | Dec 2004 | EP |
1486232 | Dec 2004 | EP |
1595497 | Nov 2005 | EP |
1120130 | Dec 2005 | EP |
1647300 | Apr 2006 | EP |
1202775 | Sep 2006 | EP |
2026870 | Feb 1980 | GB |
2079610 | Jan 1982 | GB |
9302744 | Feb 1993 | WO |
9417771 | Aug 1994 | WO |
0064336 | Nov 2000 | WO |
0108749 | Feb 2001 | WO |
0064336 | Jun 2002 | WO |
03085546 | Oct 2003 | WO |
2004036377 | Apr 2004 | WO |
2004064918 | Aug 2004 | WO |
2004069330 | Aug 2004 | WO |
2004071575 | Aug 2004 | WO |
2004075982 | Sep 2004 | WO |
2004112894 | Dec 2004 | WO |
2005007120 | Jan 2005 | WO |
2005007232 | Jan 2005 | WO |
2005028026 | Mar 2005 | WO |
2005053788 | Jun 2005 | WO |
2005067599 | Jul 2005 | WO |
2005101282 | Oct 2005 | WO |
2006014760 | Feb 2006 | WO |
2006019822 | Feb 2006 | WO |
2006050144 | May 2006 | WO |
2006122148 | Nov 2006 | WO |
2007018793 | Feb 2007 | WO |
2007066343 | Jun 2007 | WO |
2007072425 | Jun 2007 | WO |
2007124126 | Nov 2007 | WO |
2007124190 | Nov 2007 | WO |
2007124192 | Nov 2007 | WO |
2007142523 | Dec 2007 | WO |
Entry |
---|
PCT Search Report for International Application No. PCT/US2009/000379, dated May 25, 2009; 8 pgs. |
Bachman, D.,S. et al.; “Effects Of Vagal Volleys And Serotonin On Units Of Cingulate Cortex in Monkeys;” Brain Research , vol. 130 (1977). pp. 253-269. |
Bohning, D.E., et al.; “Feasibility of Vagus Nerve Stimulation—Synchronized Blood Oxygenation Level-Dependent Functional MRI,” A Journal of Clinical and Laboratory Research: Investigative Radiology; vol. 36, No. 8 (Aug. 2001); pp. 470-479. |
Boon, Paul, et al.; “Programmed and Magnet-Induced Vagus Nerve Stimulation for Refractory Epilepsy;” Journal of Clinical Neurophysiology vol. 18 No. 5; (2001); pp. 402-407. |
Clark, K.B., et al.; “Posttraining Electrical Stimulation of Vagal Afferents with Concomitant Vagal Efferent Inactivation Enhances Memory Storage Processes in the Rat,” Neurobiology of Learning and Memory, vol. 70, 364-373 (1998) Art. No. NL983863. |
Clark, K.B., et al.; “Enhanced Recognition Memory Following Vagus Nerve Stimulation in Human Subjects;” Nature Neuroscience, vol. 2, No. 1, (Jan. 1999) pp. 93-98. |
Craig, A.D. (BUD); “Distribution of Trigeminothalamic and Spinothalamic Lamina I Terminations in the Macaque Monkey;” The Journal of Comparative Neurology, vol. 447, pp. 119-148 (2004). |
DeGiorgo, Christopher M., et al.; “Vagus Nerve Stimulation: Analysis of Device Parameters in 154 Patients During the Long-Term XE5 Study;” Epilepsia, vol. 42, No. 8; pp. 1017-1020 (2001). |
Devous, Michael D., et al.; “Effects of Vagus Nerve Stimulation on Regional Cerebral Blood Flow in Treatment-Resistant Depression,” National Institute of Mental Health—42nd Annual NCDEU Meeting: Poster Session II; Poster Abstracts, Jun. 10-13, 2002, 1 page; http://www.nimh.nih.gov/ncdeu/abstracts2002/ncdeu2019.cfm. |
Hallowitz, R.A., et al.; “Effects Of Vagal Tolleys On Units Of Intralaminar and Juxtalaminar Thalamic Nuclei in Monkeys;” Brain Research, vol. 130 (1977), pp. 271-286. |
Harry, J.D., et al.; “Balancing Act: Noise is the Key to Restoring the Body's Sense of Equilibrium;” IEEE Spectrum (Apr. 2005)pp. 37-41. |
Henry, T.R., et al.; “Brain Blood-Flow Alterations Induced by Therapeutic Vagus Nerve Stimulation in Partial Epilepsy: I. Acute Effects at High and Low Levels of Stimulation;” Epilepsia vol. 39, No. 9; pp. 984-990 (1988). |
Henry, MD, T.R.; “Therapeutic Mechanisms of Vagus Nerve Stimulation” Neurology, vol. 59 Suppl. 4 (Sep. 2002); pp. S3-S14. |
King, M.D., “Effects of Short-Term Vagus Nerve Stimulation (VNS) on FOS Expression in Rat Brain Nuclei” 58th Annual Scientific Convention of the Society of Biological Psychiatry, (May 2003). |
Klapper, M.D., et al., “VNS Therapy Shows Potential Benefit in Patients with Migraine and Chronic Daily Headache After 3 to 6 Months of Treatment (Preliminary Results)” 45th Annual Scientific Meeting of the American Headache Society (Jun. 2003). |
Koo, B., “EEG Changes With Vagus Nerve Stimulation” Journal of Clinical Neurophysiology, vol. 18 No. 5 (Sep. 2001); pp. 434-441. |
Labar, D., “Vagus Nerve Stimulation for 1 Year in 269 patients on Unchanged Antiepilectic Drugs” Seizure vol. 13, (2004) pp. 392-398. |
Lockard et al., “Feasibility And Safety Of Vagal Stimulation In Monkey Model;” Epilepsia, vol. 31 (Supp. 2) (1990), pp. S20-S26. |
Liebman, K.M. et al.; “Improvement in Cognitive Function After Vagal Nerve Stimulator Implantation;” Epilepsia, vol. 39, Suppl. 6 (1998) 1 page. |
Malow, B.A., et al.; “Vagus Nerve Stimulation Reduces Daytime Sleepiness in Epilepsy Patients” Neurology 57 (2001) pp. 978-884. |
McClintock, P., “Can Noise Actually Boost Brain Power” Physics World Jul. 2002; pp. 20-21. |
Mori, T., et al.; “Noise-Induced Entrainment and Stochastic Resonance in Human Brain Waves” Physical Review Letters vol. 88, No. 21 (2002); pp. 218101-1-218101-4. |
Rugg-Gunn, F.J., et al.; “Cardic Arrhythmias in Focal Epilepsy: a Prospective Long-Term Study” www.thelancet.com vol. 364 (2004) pp. 2212-2219. |
Rutecki, P.; “Anatomical, Physiological, and Theoretical Basis for the Antiepileptic Effect of Vagus Nerve Stimulation” Epilepsia, vol. 31 Suppl. 2; S1-S6 (1990). |
Sahin, M.; et al.; “Improved Nerve Cuff Electrode Recordings with Subthreshold Anodic Currents,” IEEE Transactions on Biomedical Engineering, vol. 45, No. 8 (Aug. 1998) pp. 1044-1050. |
Schachter, S.C., et al.; “Progress in Epilepsy Research: Vagus Nerve Stimulation,” Epilepsia, vol. 39, No. 7 (1998) pp. 677-686. |
Tatum, W.O., et al.; “Ventricular Asystole During Vagus Nerve Stimulation for Epilepsy in Humans” American Academy of Neurologgy (1999) p. 1267 (See also pp. 1117, 1166, and 1265). |
Tatum, W.O., et al.; “Vagus Nerve Stimulation and Drug Reduction” Neurology, vol. 56, No. 4 (Feb. 2001) pp. 561-563. |
Terry et al.; “The Implantable Neurocybernetic Prosthesis System”, Pacing and Clinical Electrophysiology, vol. 14, No. 1 (Jan. 1991), pp. 86-93. |
Tubbs, R.S., et al.; “Left-Sided Vagus Nerve Stimulation Decreases Intracranial Pressure Without Resultant Bradycardia in the Pig: A Potential Therapeutic Modality for Humans” Child's Nervous System Original Paper; Springer-Verlag 2004. |
Valdez-Cruz, A., et al.; “Chronic Stimulation of the Cat Vagus Nerve Effect on Sleep and Behavior” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 26 (2002) pp. 113-118. |
Vonck, K., et al. “The Mechanism of Action Of Vagus Nerve Stimulation For Refractory Epilepsy—The Current Status”, Journal of Neurophysiology, vol. 18 No. 5 (2001), pp. 394-401. |
Ward, H., M.D., et al.; “Treatment-Refractory Obsessive-Compulsive Disorder: Potential Benefit of VNS Therapy” 23rd Annual Conference of the Anxiety Disorders Association of America (2007). |
Woodbury, et al., “Vagal Stimulation Reduces the Severity Of Maximal Electroshock Seizures in Intact Rats. Use of a Cuff Electrode for Stimulating And Recording”; Pacing and Clinical Electrophysiology, vol. 14 (Jan. 1991), pp. 94-107. |
Zabara, J. “Inhibition of Experimental Seizures in Canines by Repetivie Vagal Stimulation” Epilepsia vol. 33, No. 6 (1992); pp. 1005-1012. |
Dodrill, Ph.D., et al.; “Effects of Vagal Nerve Stimulation on Cognition and Quality of Life in Epilepsy;” Epilepsy and Behavior, vol. 2 (2001); pp. 46-53. |
Fromes, G. A.et al.; “Clinical Utility of On-Demand Magnet use with Vagus Nerve Stimulation;” AES Proceedings, p. 117. |
George, M.S., et al.; “Open Trial of VNS Therapy in Severe Anxiety Disorders;” 156th American Psychiatric Association Annual Meeting; May 17-22, 2003. |
George, M.S., et al.; “Vagus Nerve Stimulation: A New Tool for Brain Research and Therapy;” Social of Biological Psychiatry vol. 47 (2000) pp. 287-295. |
Fanselow, E.E., at al., “Reduction of Pentylenetetrazole-Induced Seizure Activity in Awake Rates by Seizure-Triggered Trigeminal Nerve Stimulation;” The Journal of Neuroscience, Nov. 1, 2000; vol. 20/21 ; pp. 8160-8168. |
Number | Date | Country | |
---|---|---|---|
20110213437 A9 | Sep 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11046430 | Jan 2005 | US |
Child | 12020097 | US |